Anteris Technologies (ASX: $AVR) announces re-domiciliation and Holdco IPO

Anteris Technologies Ltd (AVR) has revealed its plan to pursue re-domiciliation to the United States through schemes of arrangement, with a newly-formed Delaware corporation, Holdco, becoming the ultimate parent company of the Anteris Group. Holdco is set to seek a primary listing on Nasdaq and a secondary listing of its CDIs on ASX. The company also aims to undertake an initial public offering targeted at US investors. The re-domiciliation and Holdco IPO are intended to be completed before the end of 2024. The move is aimed at providing access to a broader range of US investors, improving visibility and global profile, and aligning the corporate and operations structure of the Anteris Group.

Executive Commentary on Re-domiciliation and Holdco IPO

The re-domiciliation to the US and the Holdco IPO represent significant strategic steps for Anteris Technologies. This move is designed to enhance our visibility and accessibility to US investors, which we believe will support the ongoing development of our DurAVR® transcatheter heart valve and the preparation and enrollment of the FDA pivotal trial for treating severe aortic stenosis. We are committed to ensuring that these initiatives are in the best interests of our shareholders and optionholders, and we look forward to their support in favor of the Schemes.

Summary of Re-domiciliation and Holdco IPO Announcement

Anteris Technologies Ltd (AVR) has announced its intention to pursue re-domiciliation to the United States through schemes of arrangement, with a newly-formed Delaware corporation, Holdco, becoming the ultimate parent company of the Anteris Group. Holdco is set to seek a primary listing on Nasdaq and a secondary listing of its CDIs on ASX. The company also intends to undertake an initial public offering targeted at US investors. The re-domiciliation and Holdco IPO are intended to be completed before the end of 2024. The move is aimed at providing access to a broader range of US investors, improving visibility and global profile, and aligning the corporate and operations structure of the Anteris Group. The company anticipates raising between US$75,000,000 and US$100,000,000 in the Holdco IPO. The announcement also includes a Scheme Implementation Deed outlining the terms and conditions of the Schemes. The company's strategic initiatives are focused on enhancing shareholder value and advancing the development of its innovative medical technologies.